Navigation Links
Research Compares MENOPUR(R) With rFSH in GnRH Antagonist IVF Cycles

ATLANTA, Oct. 20 /PRNewswire/ -- Ferring Pharmaceuticals presented an interim study analysis indicating that MENOPUR® (menotropins for injection, USP) is effective in in vitro fertilization (IVF) cycles using a gonadotropin-releasing hormone (GnRH) antagonist. The results were presented in a poster at the 65th Annual Meeting of the American Society for Reproductive Medicine (ASRM) in Atlanta, October 17-21, 2009.

MENOPUR® vs. rFSH in GnRH Antagonist Cycles Interim Study Analysis

In an interim analysis of a multicenter, randomized, open-label exploratory study of IVF cycles using a GnRH antagonist, patients were randomized prior to stimulation with either MENOPUR® or recombinant follicle stimulating hormone (rFSH), and luteal support with either ENDOMETRIN® (progesterone) Vaginal Insert 100 mg or progesterone-in-oil (PIO). The overall continuing pregnancy rate was 43.1 percent (n=143), with pregnancy rates of 46.7 percent for the MENOPUR® group (n=68) and 40.0 percent for the rFSH group (n=75). Results of the analysis indicate that MENOPUR® is effective in IVF cycles using a GnRH antagonist, and the efficacy of ENDOMETRIN® is equivalent to that of PIO for luteal support.

"We are very encouraged by these interim results," said Ed Trott, vice president, medical affairs. "We anticipate that the final results of the study will add to the growing body of evidence suggesting that hMG offers better embryo quality and higher implantation and live birth rates when compared to using rFSH alone."


MENOPUR® administered subcutaneously is indicated for the development of multiple follicles and pregnancy in the ovulatory patients participating in an ART program.

Important Safety Information

Only physicians thoroughly familiar with infertility treatment, including the risk of multiple births and adverse reactions, should prescribe MENOPUR®. MENOPUR®, like all gonadotropins, is a potent substance capable of causing mild to severe adverse reactions, including OHSS (overall incidence 3.8%), with or without pulmonary or vascular complications, in women undergoing therapy for infertility. MENOPUR® is contraindicated in women who have a high FSH level indicating primary ovarian failure; uncontrolled thyroid and adrenal dysfunction; an organic intracranial lesion such as a pituitary tumor; sex hormone dependent tumors of the reproductive tract and accessory organs; abnormal uterine bleeding of undetermined origin; ovarian cysts or enlargement not due to polycystic ovary syndrome; prior hypersensitivity to menotropins or MENOPUR®. MENOPUR® is not indicated in women who are pregnant. There are limited human data on the effects of menotropins when administered during pregnancy.


ENDOMETRIN® administered as a progesterone vaginal insert is indicated to support embryo implantation and early pregnancy by supplementation of corpus luteal function as part of an Assisted Reproductive Technology (ART) treatment for infertile women.

Important Safety Information

Only physicians thoroughly familiar with infertility treatment should prescribe ENDOMETRIN®. In clinical trials (n=808), adverse reactions that occurred at a rate greater than or equal to 2 percent included: uterine spasm (3% to 4%) and vaginal bleeding (3%). Vaginal irritation, itching, burning or discomfort, urticaria, and peripheral edema were reported at an incidence of less than 2 percent. ENDOMETRIN® is expected to have adverse reactions similar to other drugs containing progesterone (breast tenderness, bloating, mood swings, irritability, and drowsiness). ENDOMETRIN® is contraindicated in women who have or have had previous allergic reactions to progesterone or any of the ingredients in ENDOMETRIN® ; a known missed abortion or ectopic pregnancy; liver disease; known or suspected breast cancer; active arterial or venous thromboembolism or severe thrombophlebitis, or a history of these events.

About Ferring Pharmaceuticals

Ferring Pharmaceuticals, part of the Ferring Group, a privately owned, international pharmaceutical company, manufactures and markets the largest family of fertility treatments of any manufacturer in the U.S. The Company markets MENOPUR®, BRAVELLE® (urofollitropin for injection, purified), REPRONEX® (menotropins for injection, USP), NOVAREL® (chorionic gonadotropin for injection, USP) and ENDOMETRIN® in the U.S. to infertility specialists and their patients. Ferring also offers the Q-CAP(TM), the first and only needle-free reconstitution device, for use with its fertility treatments.

Ferring's line of urology products includes FIRMAGON® (degarelix for injection) and PROSED® DS (methenamine, phenyl salicylate, methylene blue, benzoic acid, hyoscyamine sulfate). Ferring's orthopaedic product includes EUFLEXXA(TM) (1% sodium hyaluronic acid). Other products include ACTHREL® (corticorelin ovine triflutate for injection) and DESMOPRESSIN.

The Ferring Group specializes in the research, development and commercialization of compounds in general and pediatric endocrinology, urology, gastroenterology, obstetrics/ gynecology, infertility and orthopaedics. For more information, call 888-337-7464 or visit or

Please visit for Full Prescribing Information for MENOPUR® and ENDOMETRIN®.

SOURCE Ferring Pharmaceuticals Inc.

SOURCE Ferring Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. comScore Study Finds the Internet a Key Component in Consumer Research on Prescriptions and Health Conditions
2. $500 Billion Health Care Spend Boosts BRIC Countries Diagnostic Imaging Sales Despite Global Recession, According to Millennium Research Group
3. New Effort to Battle Antibiotic Resistance Rallies Researchers Throughout Harvard University
4. National Institutes of Health Awards More Than $54 Million to Kaiser Permanente to Conduct Health Research
5. Outcomes Registry in Heart Attack Patients to Generate Numerous Studies; Data Quality Ensured Through Velos Clinical Research Management System
6. Two Hutchinson Center Scientists Receive a Total of $16.7 Million for Collaborative Stem Cell Research
7. Cornerstone Pharmaceuticals Adds Acclaimed Cancer Research Pioneer Robert A. Weinberg, Ph.D. to Its Scientific Advisory Board
8. Dynatronics Appoints Douglas Sampson as Vice President of Production and Research & Development
9. Peregrine Pharmaceuticals Forms Anti-Viral Research Group to Oversee Its Anti-PS Infectious Disease Collaborations
10. The Japanese Cancer Association and Debiopharm Group Present the JCA-Mauvernay Award to Dr Ushijima for his Oncology Research
11. Sigma-Aldrich(R) Receives Award From Michael J. Fox Foundation to Develop Parkinsons Disease Research Models
Post Your Comments:
(Date:10/13/2015)... Science Automation (DSA), a system integration and automation engineering firm, ... the United Kingdom (UK) as the ... . The decision to open the new office comes in ... in the medical device industry throughout the UK. ... had tremendous success over the last several years in product ...
(Date:10/13/2015)... 13, 2015  Synapse Biomedical Inc. ( ) ... (PAS) studying the use of the NeuRx ® ... enroll patients. the United States ... market-approved criteria. The PAS study group met their initial ... study has since expanded the enrollment target to 150 ...
(Date:10/13/2015)... , Oct. 13 2015 ... the "US & European markets for Meniscal ... their offering. --> ) has ... European markets for Meniscal Repair - 16 Countries ... Research and Markets ( ) has ...
Breaking Medicine Technology:
(Date:10/13/2015)... , ... October 13, 2015 , ... ... anesthesia and pain management services, today announced its partnership with WPC Healthcare ... data from disparate systems and organizes the data into an aggregated data repository ...
(Date:10/13/2015)... ... October 13, 2015 , ... Altec ... their sponsorship of the Microsoft Dynamics AXUG, GPUG and NAVUG Summits to take ... and NAVUG Summit are independent user conferences designed and led by users to ...
(Date:10/13/2015)... ... October 13, 2015 , ... Relay (, a technology company ... a significant contract that will provide its award-winning private messaging solution to Independence ... growing success of its Relay program, IBX Wire™, which now has over 550,000 ...
(Date:10/13/2015)... ... 13, 2015 , ... A child without a healthy mouth is much more ... remote invisible aligner system, has joined with Global Dental Relief (GDR) to ... aligner treatment plan purchased, SmileCareClub will donate one clinic visit to a child in ...
(Date:10/13/2015)... ... October 13, 2015 , ... Nordic ... unique health needs of new moms. Postnatal Omega-3, which has been named ... utilizes Nordic Naturals’ exclusive, new, ultra-concentrated omega-3 oil. This breakthrough oil combines ...
Breaking Medicine News(10 mins):